To determine the prognosis and prognostic factors in series of mucinous tumors of the ovary (MTO) we included 34 patients in our retrospective review. Criteria were defined: 1.centralized histological review by our expert pathologist; 2. high risk of peritoneal pseudomyxoma or any synchronous malignant tumor in the abdominal cavity; 3. available data on the management and outcomes of patients. We found specific markers overexpression in mucinous ovarian tumors compared to their normal ovary tissues and serous type ovarian tumors by analysis of serum CA 19,9, CEA and immunohistochemistry. These results suggest that mucinous tumors of the ovary have distinctive cancergenesis and may attribute to the progression of the mucinous ovarian cancer.


  1. Teramukai S., K. Ochiai, H. Tada, A new prognostic index of advanced epithelial ovarian cancer (PIEPOC): A JMTO OC01-01 study // ASCО 2006, abs. 5061.
  2. Pecorelli Staging Classification and clinical practice Guidelines for Gynacological Cancer. A collaboration between FIGO and IGCS 2006, Kuala Lumpur, FIGO.
  3. Чекалова М.А., Шабанов М.А., Поддубная И.В., Горелова И.А. Ультразвуковая диагностика муцинозных новообразований яичников // Ультразвуковая и функциональная диагностика. 2006. № 2. С. 39-47.
  4. Liu P., Moon J., Alberts D.S. et al. A modified CA-125 progression criterion in ovarian cancer (OC) patients (pts) receiving maintenance treatment following complete clinical response (cCR) to primary therapy // ASCO 2006, abs.5080.
  5. Tanabe H., Katsumata N., Matsumoto K. CA125 nadir as a prognostic factor in advanced ovarian carcinoma: A retrospective study of 84 patients achieving clinical CR // ASCO 2006, Abs. 5007.
  6. Nadal R.M. , B. M. Ojeda, V. Artigas, Stratification of the normal range of CA125 after chemotherapy as a predictive factor in carcinoma of the ovary // ASCO 2006, abs. 5059.
  7. Aabo K., Adams M., Adnitt P. et al. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists Group // Br. J. Cancer. 1998; 78: 1479-87.
  8. Berek J.S., Bertelsen K., du Bois A. et al. Epithelial ovarian cancer: 1998 consensus statements. // Ann. Oncol. 1999. 10 Suppl 1: 87-92.
  9. Hoskins W.J. Surgical staging and cytoreductive surgery of epithelial ovarian cancer // Cancer. 1993;71: 1534-1540.
  10. Горелова И.А.// Муцинозные опухоли яичников различного потенциала злокачественности. Автореф. на соиск. степ. канд. мед. наук. 2008. Москва.
  11. Yamao K., Yanagisawa A., Takahashi K. Clinicopathological Features and Prognosis of Mucinous Cystic Neoplasm With Ovarian-Type Stroma: A Multi-Institutional Study of the Japan Pancreas Society // Pancreas. 2010 Sep 29.
  12. Schmuck R.B., Pietzner K., Buckendahl A. Cervical manifestation of a borderline type ovarian cancer with pseudomyxoma peritonei - a case report // Anticancer Res. 2010. Jul; 30(7):2991-4.
  13. Piver S.M. Optimal surgical therapy in stage I-II ovarian malignecies // Int. J. Radiat Oncol. Biol. Phys. 1982; 8: 247-249.
  14. Landoni F., A. Maggioni, T. Dell'anna Randomized trial of systematic lymphadenectomy (LY) vs nodal sampling (SA) at second look surgery (SLS) in ovarian cancer patients: Final results. // ASCO 2006, Abs.5068.
  15. Young R.C., Brady M.F. Randomized Clinical Trial of adjuvant treatment of women with early (FIGO I-IIa high risk) ovarian cancer - GOG Proc. // ASCO 1999 :18: 357a.
  16. Bagley C.M., Young R.S., Schein P.S. Ovarian carcinoma metastatic to the diaphragm - frequently undiagnosed at laparotomy // Am. J. Obstet Gynecol. 1973, 116: 397-400.
  17. Харитонова Т.П., Поддубная И.В., Мартынова Ж.А. и соавт. Оптимизация лечения распространенного рака яичников // Врач. 2008. № 8. С. 35-36.
  18. Tang L., Yang J., Ng S.K., Rodriguez N. Autoantibody profiling to identify biomarkers of key pathogenic pathways in mucinous ovarian cancer // Eur. J. Cancer. 2010 Jan;46(1):170-9.
  19. Heinzelmann-Schwarz V.A., Gardiner-Garden M., Henshall S.M. A distinct molecular profile associated with mucinous epithelial ovarian cancer // Br. J. of Cancer. 2006. 94, 904-913.
  20. Bolis G., Colombo N., Pecorelli S. Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatmant or chonic phosphate (32P) G.I.C.O.G. // Ann. Oncol. 1995: 6 : 887-93.
  21. Wamunyokoli F.W., Bnome J.Y., Lee C.M. Expression profiling of mucinous tumor of theovary indentify genes of clinic-pathologic impotance // Clin. Cancer Res. 2006, 12(3P). P. 690-700.
  22. Nomura Kouichi, Shigeo Aizawa, Hiroshi Hano. Ovarian mucinous border-line tumors of intestinal type without intraepithelial carcinoma: Are they still tumors of low malignant potential? // Pathology International, June 2004, Vol. 54, Issue 6. P. 420-24.
  23. Kolomainen D.F., A'Hern R., Coxon F.Y. et. al. Can patients with relapsed, previously untreated, stage i epithelial ovarian cancer be successfully treated with salvage therapy? // J. Clin. Oncol. 2003. Vol. 21, Issue 16: 3113-18.
  24. Lee J.H., Zhang X., Shin B.K., Lee E.S. Mac-2 binding protein and galectin-3 expression in mucinous tumours of the ovary: an annealing control primer system and immunohistochemical study // J. Pathology. 2009;41(3):229-33.



Abstract - 264

PDF (Russian) - 1036


Article Metrics

Metrics Loading ...


Copyright (c) 2010 Kedrova A.G., Levakov S.A., Shablovskiy O.R., Vanke N.S., Nechaeva O.V., Maksimenko T.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies